Immunoassay for the detection of ligands

• US 5,895,750 A
• Filed: 05/03/1995
• Issued: 04/20/1999
• Est. Priority Date: 05/10/1984
• Status: Expired due to Term

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Mushahwar, Isa K., Stuckmann, Karen V., Decker, Richard H.
• Primary Examiner(s): Scheiner, Toni R.
• Application Number:
  US08/434,251
• Time in Patent Office: 1,448 Days
• Field of Search: 435/5, 435/6, 435/7.23, 435/7.32, 435/7.5, 435/7.9, 435/7.92, 435/7.93, 435/804, 436/501.518, 436/530
• US Class Current: 435/7.5
• CPC Class Codes: G01N 33/532 Production of labelled immunochemicals
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms

Abstract

A biotin-antibiotin immunoassay comprises coating a solid phase with a ligand-specific binding material, reacting the solid phase with a test sample, reacting the solid phase with the biotin-labeled form of the ligand-specific binding material and antibiotin labeled with a suitable marker. The marker is then measured to detect the amount of ligand present in the test sample.

Claims

1. An immunoassay for detecting a ligand comprising:

a) immobilizing a ligand-specific binding material onto a solid phase;

b) reacting the solid phase with a test sample;

c) reacting the solid phase with a biotin-labeled ligand-specific binding material;

d) reacting the solid phase with antibiotin labeled with a marker;

e) separating unreacted reagents from the solid phase; and

f) measuring the amount of the marker in the solid phase or in the unreacted reagents to detect the amount of ligand present in the sample.

2. The immunoassay of claim 1 wherein the marker is an enzyme.

3. The immunoassay of claim 1 wherein the marker is a radioisotope.

4. The immunoassay of claim 1 wherein steps (b), (c) and (d) are performed simultaneously.

5. The immunoassay of claim 1 wherein steps (c) and (d) are performed simultaneously.

6. The immunoassay of claim 1 wherein the ligand is an antigen.

7. The immunoassay of claim 1 wherein the ligand is an antibody.

8. The immunoassay of claim 1 wherein the ligand is selected from the group consisting of viral, bacterial, fungal, rickettsial and tumor-associated antigens and their corresponding antibodies.

9. The immunoassay of claim 1 wherein the ligand-specific binding material is hepatitis B surface antigen.

10. The immunoassay of claim 1 wherein the solid phase is selected from the group consisting of polystyrene beads, test tubes, microtiter plates, nitrocellulose sheets, and derivatized paper.

11. An immunoassay for detecting a ligand comprising:

a) immobilizing a ligand-specific binding material onto a solid phase;

b) reacting the solid phase with a human biological fluid;

c) reacting the solid phase with a biotin-labeled ligand;

d) reacting the solid phase with an enzyme-labeled antibiotin;

e) separating unreacted reagents from the solid phase; and

f) measuring amount of the enzyme in the solid phase or in the unreacted reagents to detect the amount of ligand present in the human biological fluid.

12. The immunoassay of claim 11 wherein the ligand is an antibody to hepatitis B surface antigen.

13. The immunoassay of claim 11 wherein the solid phase comprises a polystyrene bead, test tube, microtiter plate, nitrocellulose sheet or derivatized paper.

14. An immunoassay for detecting a ligand which may be present in a biological fluid test sample, comprising:

(a) reacting the test sample with a solid phase to which a ligand-specific binding material has been immobilized;

(b) reacting said solid phase with a biotin-labeled specific binding material;

(c) reacting said solid phase with antibiotin labeled with a marker;

(d) separating unreacted reagents from the solid phase;

(e) measuring the amount of the marker in the solid phase or in the unreacted reagents to detect the amount of ligand present in the sample.

15. The immunoassay of claim 14 wherein the marker is selected from the group consisting of an enzyme and a radioisotope.

16. The immunoassay of claim 14 wherein steps (a), (b) and (c) are performed simultaneously.

17. The immunoassay of claims 14 wherein steps (b) and (c) are performed simultaneously.

18. The immunoassay of claim 14 wherein the solid phase is selected from the group consisting of polystyrene beads, test tubes, microtiter plates, nitrocellulose sheets, and derivatized paper.

19. A competitive immunoassay for detecting a ligand which may be present in a biological fluid sample, comprising:

(a) reacting the test sample with a solid phase to which a ligand-specific binding material has been attached, a biotin-labeled ligand and antibiotin labeled with a marker;

(b) separating unreacted reagents from the solid phase;

(c) measuring the amount of the marker in the solid phase or in the unreacted reagents to detect the amount of ligand present in the sample.

20. The immunoassay of claim 19 wherein the marker is selected from the group consisting of an enzyme and a radioisotope.

21. The immunoassay of claim 19 wherein the solid phase is selected from the group consisting of polystyrene beads, test tubes, microtiter plates, nitrocellulose sheets, and derivatized paper.